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Background: Human prion diseases are caused by abnormal accumulation of misfolded prion protein in the brain
tissue. Inherited prion diseases, including familial Creutzfeldt-Jakob disease (fCJD), are associated with mutations of
the prion protein gene (PRNP). The glutamate (E)-to-lysine (K) substitution at codon 200 (E200K) in PRNP is the most
common pathogenic mutation causing fCJD, but the E200K pathogenic mutation alone is regarded insufficient to
cause prion diseases; thus, additional unidentified factors are proposed to explain the penetrance of E200K-dependent
fCJD. Here, exome differences and biological network analysis between fCJD patients with E200K and healthy
individuals, including a non-CJD individual with E200K, were analysed to gain new insights into possible mechanisms
for CJD in individuals carrying E200K.
Methods: Exome sequencing of the three CJD patients with E200K and 11 of the family of one patient (case1) were
performed using the Illumina HiSeq 2000. The exome sequences of 24 Healthy Koreans were used as control. The
bioinformatic analysis of the exome sequences was performed using the CLC Genomics Workbench v5.5. Sanger
sequencing for variants validation was processed using a BigDye Terminator Cycle Sequencing Kit and an ABI 3730xl
automated sequencer. Biological networks were created using Cytoscape (v2.8.3 and v3.0.2) and Pathway Studio
9.0 software.
Results: Nineteen sites were only observed in healthy individuals. Four proteins (NRXN2, KLKB1, KARS, and LAMA3)
that harbour rarely observed single-nucleotide variants showed biological interactions that are associated with prion
diseases and/or prion protein in our biological network analysis.
Conclusion: Through this study, we confirmed that individuals can have a CJD-free life, even if they carry a pathogenic
E200K mutation. Our research provides a possible mechanism that involves a candidate protective factor; this could be
exploited to prevent fCJD onset in individuals carrying E200K.
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Transmissible spongiform encephalopathies (TSE), also
called prion diseases, are rare fatal neurodegenerative
disorders that affect humans and animals. TSE are char-
acterized at the pathological level by abnormal accu-
mulation of misfolding prion protein (PrPsc) affecting
the central nervous system (CNS) [1,2]. In most cases,
transmission of PrPsc has been proven in animal models
including primates and rodents; this has established
PrPsc as the transmissible agent of diseases [3-5]. In hu-
mans, the causative agent is encoded by the prion protein
gene (PRNP) on chromosome 20p13. The incubation
period for prion diseases observed in humans and animals
is influenced by polymorphisms or mutations in PRNP.
Pathogenic mutations in prion proteins that cause inher-
ited prion diseases (IPD) are responsible for 10–15% of
cases [6-8]. IPD have traditionally been classified as fa-
milial Creutzfeldt-Jakob disease (fCJD), fatal familial inso-
mnia (FFI), and Gerstmann-Straussler-Scheinker syndrome
(GSS). P102L, P105L, A117V, Y145stop, D178N, V180I,
F198S, E200K, and V203I mutations in prion proteins are
highly correlated with the pathogenicity of IPD [3-5,9-22].
The E200K substitution within PRNP is a major causa-
tive mutation of IPD [6,23]. The clinical features of fCJD
patients with E200K are similar to those of sporadic CJD
patients, and the median age of onset of CJD patients
with E200K is 58, with a median disease duration of
seven months [24]. The E200K mutation was first re-
ported in 1989, and has since been found in North
American Caucasians, Slovakians, Polish, German, Tu-
nisian Jewish, Greek, Libyan Jews, and Chilean popula-
tions [13,25]. Although E200K is reportedly a causative
mutation for fCJD, not all cases have a familial history.
The mutation has also been observed in healthy individ-
uals who are already above the median age for E200K-
associated CJD; remarkably, in one case, an individual
over 80 years of age with the E200K mutant died of non-
CJD related causes [26,27].
The reported penetrance for CJD with E200K is 56–
59.5% in individuals below 80 years of age, and, depend-
ing on the population under study, rises to 80–100% in
individuals above 80 years of age [13,27-29]. This dem-
onstrates that most of the individuals with E200K can be
regarded as suffering from CJD after the median age, but
that some individuals appear to survive without the
symptoms of CJD. This has led scientists to propose that
genetic background can contribute to the delayed onset
of CJD [26].
A Korean CJD patient with E200K who was presented
to us was presumed to represent a sporadic case, since
there was no previous family history of CJD [30]. Three
generations of the patient’s family (n = 12) provided us
with their epidemiological details and whole blood sam-
ples; we investigated the PRNP genotypes of this pedigreeand found that all of them were 129M homozygotes.
E200K was observed in eight members of the family, in-
cluding the patient. Five were 200E homozygotes, and
200K homozygotes were not observed.
Interestingly, the mother of the proband (born in 1927)
was E200K heterozygous, but she did not have any symp-
toms related to neurodegenerative disorders, despite the
fact that she was well over the median age for disease on-
set. This presentation makes the case extremely rare glo-
bally, and it is the first such case in Korea. We decided
that follow-up studies of this family might further our un-
derstanding not only of the mechanisms by which E200K
causes CJD, but also identify clusters of genetic polymor-
phisms that underlie neuroprotection.
Here, we report the genotype patterns and differences
in the exome sequences between the above-mentioned
family, CJD patients with E200K, and healthy individ-
uals. We also discuss the biological network analysis
undertaken to infer relationships between genotypes and
prion disease onset.
Results and discussion
Two types of variant filtering strategies were used (see
Methods). Validation studies revealed that 19 of 24 sites
were validated as SNVs, with the rest being false posi-
tive (Table 1). Primer sequences of 24 sites are listed in
Additional file 1: Table S1. All 19 validated SNVs were
detected on autosomes. The biological data and official
full name associated with each protein of the 19 SNVs-
containing genes are listed in Additional file 2: Table S2
and Additional file 3: Table S3. None of the genes have
previously been associated with prion diseases, with the
exception of NRXN2, which was reported to be down-
regulated in mice infected with PrPsc [31]. Although the
second variant filtering strategy was more relaxed than
the first, only five variants met the criteria. However, all
of them were confirmed as false positives. There are at
least three hypothetical reasons to explain this. First,
E200K may be the sole pathogenic mutation associated
with CJD in these individuals. Second, CJD patients with
E200K may indeed carry additional pathology-related
mutations, but these may be already published, rather
than de novo mutations. Third, the fact that we selected
individuals with the E200K mutation in the first filtering
strategy might influence the analysis with respect to
prion disease onset or incubation period. Specifically,
this may imply that the 85-year-old non-CJD individual
with the E200K mutation might also carry protective
SNVs at other loci. E200K is unlikely to be the sole mu-
tation that determines CJD onset, since there are some
elderly individuals (age, up to 85 years) in this study.
CJD is a rare neurodegenerative disorder, and there is a
small possibility of disease identification in elderly in-
dividuals who carry E200K mutation and are healthy.
Table 1 The information of the 24 sites that were directly sequenced and the genotypes of analysed individuals
PRNP mutation E200K E200K E200K E200K WT E200K E200K E200K WT E200K
























1948 non-descript 1935 1927 1950 1952 1955 1957 1962 1969
Filtering strategy 1
1 27,268,000 NUDC G/A GG GG GG GA GG GA GA GA GG GG
1 42,049,603 HIVEP3 C/T CC CC CC CT CT CC CC CC CT CC
2 64,199,317 VPS54 G/A GG GG GG GA GG GG GA GA GA GG
2 233,346,498 ECEL1 C/T CC CC CC CT CC CC CC CC CT CC
3 124,896,625 SLC12A8 A/G AA AA AA AG AG AA AG AG AA AA
4 187,153,290 KLKB1 C/T CC CC CC CT CC CC CT CC CC CC
5 139,884,478 ANKHD1-EIF4EBP3 G/C GG GG GG GC GG GG GG GG GC GG
6 159,185,617 SYTL3 T/C TT TT TT TC TC TC TT TC TT TT
8 2,088,717 MYOM2 G/T GG GG GG GT GT GT GT GG GT GG
9 18,950,859 FAM154A C/T CC CC CC CT CT CT CT CC CT CC
10 24,831,649 KIAA1217 C/T CC CC CC CT CT CT CC CC CC CC
11 27,016,411 FIBIN A/G AA AA AA AG FL AA AG AG AG AA
11 36,250,774 LDLRAD3 G/T GG GG GG GT GG GT GG GG GG GG
11 64,453,195 NRXN2 C/A CC CC CC CA CC CA CA CA CC CC
13 39,588,100 PROSER1 G/A GG GG GG GA GG GG GG GG GG GG
16 75,669,878 KARS A/G AA AA AA AG AG AA AA AG AA AA
17 59,489,425 C17orf82 C/G CC CC CC CG CG CG CC CG CG CC
18 21,485,578 LAMA3 G/C GG GG GG GC GC GC GC GG GC GG
19 4,359,190 MPND C/T CC CC CC CT CT CT CC CC CC CC
Filtering strategy 2
17 45,219,336 CDC27 T/A TT TT TT TT TT TT TT TT TT TT
19 501,786 MADCAM1 C/A CC CC CC CC CC CC CC CC CC CC
19 50,510,999
VRK3
A/T TT TT TT TT TT TT TT TT TT TT
19 50,511,000 C/T TT TT TT TT TT TT TT TT TT TT




















Table 1 The information of the 24 sites that were directly sequenced and the genotypes of analysed individuals (Continued)

































1971 1975 1977 1981 1983 1969 1975 1976 1977 1980 1982 1983 1983 1984 1987
Filtering strategy 1
GG GG GG GA GG GG GG GG GG GG GG GG GG GG GG
CC CC CC CC CC CC CT CC CC CC CC CC CC CC CC
GG GG GA GA GG GG GG GA GG GG GG GG GG GG GG
CC CC CC CC CC CC CT CC CC CT CT CC CC CC CC
AA AA AG AG AG AA AA AA AA AA AA AA AA AA AA
CC CC CC CC CC CC CC CC CC CC CC CC CC CC CC
GG GG GG GG GG GG GG GG GG GG GG GG GG GG GG
TT TT TT TC TC TT TT TT TT TT TT TT TT TT TT
GG GG GT GG GG GG GG GG GG GG GG GG GG GG GG
CC CC CC CC CC CC CC CC CC CC CC CC CC CC CC
CC CC CC CC CC CC CC CC CC CC CC CC CC CC CC
AA AA AA AG AA AA AA AG AA AA AA AA AA AA AG
GG GG GG GG GG GG GG GG GG GG GG GG GG GG GG
CC CC CC CA CC CC CC CC CC CC CC CC CC CC CC
GG GG GG GG GG GG GG GG GG GG GG GG GG GG GG
AA AA AA AA AG AA AA AA AA AA AA AA AA AA AA
CC CC CC CC CG CC CC CC CC CC CC CC CC CC CC
GG GG GG GG GG GG GG GG GG GG GG GG GG GG GG
CC CC CC CC CC CC CC CC CC CC CC CC CC CC CC
Filtering strategy 2
TT TT TT TT TT TT TT TT TT TT TT TT TT TT TT
CC CC CC CC CC CC CC CC CC CC CC CC CC CC CC
TT TT TT TT TT TT TT TT TT TT TT TT TT TT TT
TT TT TT TT TT TT TT TT TT TT TT TT TT TT TT
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might be discovered by comparing the exome of such in-
dividuals to other groups. In light of these considera-
tions, we discarded the first two hypotheses and instead
focused on the third possibility.
The 63-year-old proband (Case 1) is the eldest progeny
of an 84-year-old non-CJD individual with the E200K
mutation (Family Member 1, hereafter FM1); the rest of
the progeny are younger than the proband by about 2–
17 years. The 19 validated SNVs were not found in the
proband and their sibling, which is expected as all muta-
tions observed in the proband were filtered during the
first filtering strategy. Between 5 and 10 variations were
observed in the other siblings. FM7 and FM9 are hetero-
zygous for E200K, and FM8 is homozygous for the wild-
type E200 variant. Nucleotide variants in all three CJD
patients with E200K were homozygous, and identical to
the reference nucleotide sequence in dbSNP 132; the
single-nucleotide variations (SNVs) in the mother of the
proband were heterozygous and contained SNVs that have
not been previously reported for dbSNP 132. NucleotideFigure 1 Interaction network among 24 seed nodes (marked as black
using three Cytoscape plug-ins. Six seed nodes (KLKB1, KARS, NRXN2, LA
criteria were annotated by red squares and indicated by red arrows. The si
and indicated by black arrows. The apoptosis cluster (path: hsa04210) was
(GO: 0006916), induction of apoptosis (GO: 0006917), induction of apop
(GO: 0042981), and positive regulation of apoptosis (GO: 0043065)].variations in PROSER1 were only observed in FM1, but
the biological functions of this proline and serine-rich
protein are unknown. We also found SNVs in NUDC,
KLKB1, and NRXN2; these were specifically present in
non-CJD E200K individuals, but not in CJD patients with
E200K counterparts. SNVs in 10 healthy individuals with
no family history of CJD were observed in four genes
(HIVEP3, VPS54, ECEL1, and FIBIN). Thus, these four
SNVs were considered as relatively common among the
general Korean population.
We used biological networking programs to gain new
insight into possible mechanisms that protect individuals
carrying E200K against CJD. The 19 proteins associated
with SNVs in our study, and 5 proteins that are reported
as prion disease-related, such as PRNP, prion protein
doublet (PRND), prion protein testis-specific (PRNT),
shadow of prion protein (SPRN), and apolipoprotein E
(APOE), were used as seed proteins.
A total of 104 nodes, including 24 seed nodes, were
identified (Figure 1). The average number of neighbours
of nodes was 4.327, with the exception of PRNT, whichcircle) and their 80 interacted nodes (marked as grey circle)
MA3, PRNP, and APOE) clustered according to the KEGG pathway
x interaction nodes with seed node were annotated by black squares
expanded using GO data [apoptosis (GO: 0006915), anti-apoptosis
tosis by intracellular signals (GO: 0008629), regulation of apoptosis
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harbouring validated SNVs, only four of them (KLKB1,
KARS, NRXN2, and LAMA3) were clustered by Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway
criteria.
PRNP and APOE, which are within the neurodegener-
ative disorder and apoptosis-related seed nodes, were
linked with Kininogen1 (KNG1) and plasminogen (PLG),
which are apoptosis- and complement and coagulation
cascade-related proteins [32-34]. KNG1 was linked with
KLKB1, which was one of the seed nodes [35-39].
LAMA3 was also linked with PLG in our study. Consist-
ent with this, LAMA3 is reported to contain a cleavage
site for plasmin, the activated form of PLG [40].
PRNP has been previously linked with growth factor
receptor bound protein 2 (GRB2) [41]. GRB2 is related
to proteins that are implicated in neurodegenerative dis-
eases (path: hsa01510), MAPK-signalling pathway (path:
hsa04010), and Huntington's disease (path: hsa05040).
GRB2 directly interacts with FRS3 [42], which is itself
related to proteins involved in the fibroblast growth fac-
tor receptor signalling pathway, and signal transduction
(GO: 0008543 and 0007165, respectively). FRS3 interacts
with KARS, which is one of the seed proteins in the
current study [43]. However, only a low-level biological
interaction between FRS3 and KARS was reported. Hence,
the relevance of KARS to prion disease at this stage re-
mains unclear.Figure 2 Interaction network using Pathway studio. Interactions bet
are marked as red circles. PLG and TNF are shown as significant intera
as diamond-square.Interaction between PRNP and PVRL1 (also called PRR)
was observed, although a strong relationship between the
two was not evident from the publication [44]. Although
PRNP was previously associated with cell adhesion mole-
cules (CAMs) such as neural CAM1 (N-CAM1), neural
CAM2 (N-CAM2) and neural adhesion molecule F3 (con-
tactin1) [44], there are no reports of a direct relationship
between PRNP and PVRL1. Thus, we believe the PRNP/
PVRL1 interaction was false. PVRL1 was linked with
MLLT4, and a previous report says that it interacts with
MLLT4 (also called Afadin), a PDZ domain-containing
protein [45-47]. MLLT4 was linked to NRXN2, which is
one of the seed proteins in this study [48]. It is known that
C-terminal peptides of the NRXN2 sequence can interact
with the PDZ domain of MLLT4.
Biological network analysis using Pathway studio v9
identified four proteins, namely, KLKB1, LAMA3, KARS,
and VPS54 (Figure 2). VPS54 and KLKB1 were identified
since they have interactions with tumour necrosis factor
(TNF), rather than with prion diseases and/or prion pro-
tein; they were thus excluded from the network analysis.
LAMA3 and KARS were identified because of indirect
interaction with prion protein and prion diseases; they
were therefore subjected to follow-up analysis to deter-
mine whether they were associated with mechanisms that
protect against prion disease.
LAMA3 is located at 18q11.2, and a de novo mutation
(K2180N) was observed in this study. The C-terminalween nodes are denoted by coloured arrows or lines. Seed nodes
ctions with the seed nodes, PRNP, prion diseases were marked
Lee et al. BMC Medical Genomics 2014, 7:52 Page 7 of 11
http://www.biomedcentral.com/1755-8794/7/52part of LAMA3 forms a compact globular domain,
called the G domain, which is divided into subdomains
G1–G5; the G1 subdomain is a plasmin-binding site,
and the G4 subdomain contains a plasmin cleavage site
[40]. PLG is reported to bind a lysine-rich portion of
PrP, and in doing so can stimulate propagation of PrPsc.
L-Lysine has a role in blocking plasminogen-mediated
stimulation of PrPsc propagation [49,50].
Aminoacyl-tRNA synthetases (ARSs) ligate specific
amino acids to their cognate tRNAs for protein synthe-
sis, and human lysyl-tRNA synthetase (KARS) are the
one of the ARSs for lysine. The Y201H mutation in
KARS was detected as a de novo mutant; however, this
mutation has previously been published in dbSNP build
134 as rs150529876. However, rs150529876 is scarcely
found in East Asian populations referred to in the 1000
Genome allele frequencies data, which confirms that it is
a very rarely detected variant in human population. The
Y201H mutation might alter the levels of lysine in the
human body, and may favour the interaction between
PLG and lysine, instead of with PrPsc. Possibly, this might
ultimately change the incubation period prior to CJD
onset.
KARS is also known to induce secretion of the proin-
flammatory cytokine TNF from macrophages [51]. Lack
of follicular dendritic cells (FDCs) was observed in TNF-
deficient (TNF−/−) mice [52], and these animals do not
accumulate scrapie in their spleens upon challenge with
the ME7 scrapie strain [53]. This is likely since mature
FDCs are required for PrPsc aggregation. Thus, we suggest
that the Y201H mutation in KARS engenders a failure of
TNF induction, which in turn prevents PrPsc accumula-
tion. We consider that this mutant form of KARS leads to
an increased incubation period for prion diseases.
Conclusions
In summary, we identified 19 SNVs that were differen-
tially present in a healthy, 86-year-old individual with
E200K, and in CJD patients with E200K. Each of these
19 SNVs is a candidate protective factor against E200K-
associated CJD, since to date they were only observed
in healthy individuals. However, longer follow-up studies
of the family are required to definitively conclude that
these 19 SNVs are CJD-protective factors. Our biological
network analysis may also explain why FM1, who is the
mother of the proband, does not have CJD symptoms,
even though she has the E200K pathogenic mutation.
Four proteins (NRXN2, KLKB1, KARS, and LAMA3)
that harbour rarely observed SNVs have biological inter-
actions that are associated with prion diseases and/or
prion protein. However, we could not find significantly
strong evidence that the other 15 proteins that harbour
de novo SNVs had a biologically relevant association
with prion diseases.Through this study, we confirmed that individuals can
have a CJD-free life, even if they harbour the pathogenic
E200K mutation, and we provide possible protective me-
chanisms to explain this observation. Our research pro-
vides fundamental insight into the mechanisms that
underlie the onset of prion disease, and suggests thera-
peutic strategies to treat E200K-associated CJD. We ex-
pect that ambiguous personal susceptibility on PRNP
mutation causing fCJD can be defined through further
studies of combined interpretation of biological network
analysis derived from next-generation sequencing of in-
dividual genomes and clinical information.
Methods
Subjects
This study was approved by Institutional Review Board,
Korea Centers for Disease Control and Prevention (IRB
No. 2010-02CON-06-P). Written informed consent was
obtained from the participants or legal guardian of each
patient.
Three CJD patients
All three CJD patients with E200K were described in this
study, and they were South Korean natives. Case 1 was
born in 1948, and was presumed to have developed symp-
toms in August 2011. The birth date of CJD Case 2 was
not recorded. The patient first showed symptoms of CJD
on January 8, 2011. Case 3 was born in 1935, and the pa-
tient first showed symptoms of CJD on March 14, 2010.
All patients informed us that did not have a family history
of CJD; thus, all three CJD patients with the E200K muta-
tion were regarded as sporadic-like cases.
12 individuals in the family of case 1
The three-generation family (n = 12) of case 1 generously
contributed their time and materials to this study. The
pedigree of the family was described using the GenoPro
(http://www.genopro.com) pedigree drawing program
(Figure 3).
Healthy Korean exome sequences
The exome sequences of 14 healthy Koreans stored in
Division of Center for Genome Science in KNIH were
used as control for variation filtering.
10 randomly selected healthy individuals
Since DNA samples for 14 healthy Korean described
above were not stored, DNA samples from 10 healthy
individual volunteers in their 20s–40s were selected for
variant validation.
DNA extraction
gDNA samples were extracted from the individuals de-











































































D. 50s D. 50s D. 50s
Proband
CJD patients with E200K
Non CJD individuals with E200K
Non CJD individuals with wild type
Figure 3 Pedigree of a three-generation family of case 1. Circles denote female subjects, squares denote male subjects, and symbols with
diagonals denote dead subjects. The CJD allele status is explained in legend located in the upper right panel. The proband is marked with a
black arrow. The age of each individual is noted in each symbol, and year of birth is noted upper part of each symbol. Died individuals were
denoted as “X in a square” and their ages at death are shown above the square.
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samples using QIAamp DNA Blood Mini Kit (QIAGEN,
Korea), according to the manufacturer’s instructions. The
extracted DNA was quantified using the Quant-iT Pico-
Green dsDNA kit (Invitrogen, Carlsbad, CA).
Exome sequencing
Exome sequencing of the three CJD patients with E200K
and 11 of the three-generation family of Case 1 were
performed using the Solexa sequencing technology plat-
form (HiSeq2000, Illumina, San Diego, CA), following
the manufacturer’s instructions. Exome sequencing of
FM 7 was excluded since the quantity of gDNA (<1 μg)
was not sufficient in this case.
Exome capture libraries and sequencing
Three micrograms of the extracted DNA was randomly
sheared using the Covaris System to generate ~150-bp
inserts. The sonicated DNA was end-repaired using T4
DNA polymerase and Klenow polymerase, and Illumina
paired-end adaptor oligonucleotides were ligated to the
sticky ends. Ligated DNA was size-selected for lengths
between 200 and 250 bp. The purified DNA library was
hybridized with SureSelect Human All Exons probe set
(Agilent, Santa Clara, CA) to capture 50-Mb targeted
exons following the manufacturer’s instructions. Cap-
tured libraries were loaded onto the Illumina flow cell
for sequencing on the Illumina HiSeq2000 instrument.
Mapping and variations detection
Sequence reads mapping was performed using CLC
Genomics Workbench v5.5 (CLC Bio, Aarhus, Denmark)with the human reference genome (GRCh37/hg19, dbSNP
build 132). Variant calling was performed with default pa-
rameters. In the mapping steps, an average of 5.6 gigabases
of uniquely mapping reads were obtained, and 3.6 giga-
bases of uniquely mapping reads were aligned on target
per sample, with an average of 64% of all reads mapping
on target. Approximately 86% of bases have basecall qual-
ity scores were over Q30 (Phred score of 30) per sample.
Variants filtering
Only variants showing different variation frequencies
between CJD patients and non-CJD individuals were se-
lected. Next, only non-synonymous variants were selec-
ted, and then variant filtering was performed based on
the hypothesis that the mutation underlying familial CJD
with E200K was rarely present in the general population
(Figure 4). Nucleotide variants presented in dbSNP build
132 were filtered out. We then excluded variants having
depth of coverage below 20×. Two types of variant filter-
ing strategy were used. For the first filtering strategy, ob-
served nucleotide variants in the 85-year-old non-CJD
individual with E200K, but not observed in the three
CJD patients with E200K. For the second filtering strat-
egy, we only observed nucleotide variants in the three
CJD patients with E200K. However, none of the sites
were selected for the second strategy. Thus, the second
filtering condition was more relaxed than that of the
first. This meant that five variants were selected even
though coverage was lower than 20×. A total of 48 sites
were selected, but only 24 sites were analysed in the
follow-up validation process, as we experienced PCR pri-
mer failures with the remaining samples.
Figure 4 Variant filtering strategy. Overview of variant filtering of whole exome sequencing data.
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PCR primer sets and their annealing temperature are de-
scribed in Additional file 1: Table S1. The final volume
of the PCR was 10 μl, consisting of 10 ng DNA, 0.5 μM
each primer pair, 0.25 mM dNTPs, 3 mM MgCl2,
1 μl of 10× reaction buffer, and 0.25 U Taq DNA polyme-
rase (Intron Biotechnology, Seongnam-Si, Gyeonggi-do,
Korea). The PCR reaction was performed using 96-Well
GeneAmp PCR System 9700 (Applied Biosystems, Foster
City, CA) under the following conditions: initial dena-
turation at 94°C for 5 min, followed by 35 cycles of de-
naturation at 94°C for 30 s, annealing at 60°C for 30 s,
initial extension at 72°C for 30–60 s, and final extension at
72°C for 10 min. The PCR products were purified using a
MultiScreen 384-PCR Filter Plate (Millipore, Billerica,
MA). The purified products were then sequenced using a
BigDye Terminator Cycle Sequencing Kit and an ABI
3730xl automated sequencer (Applied Biosystems, Foster
City, CA). The sequencing primers were the same as those
used for the PCR amplification.
Biological network analysis
1) Cytoscape (http://www.cytoscape.org/)
Cytoscape and three plug-ins, MiMI v3.1.1 (http://mimi.
ncibi.org/MimiWeb/main-page.jsp), GeneMania v3.2.1
(http://www.genemania.org/), and Agilent Literature
Search 3.0.3 beta (http://www.agilent.com/labs/research/
litsearch.html) were used to construct a biological net-
work. Due to compatibility issues, we used MiMI in
Cytoscape v2.8.3 rather than v3.0.2. Next, all three
networks were merged and visualized in Cytoscape v3.0.2.All nodes were clustered automatically using listed KEGG
pathway criteria and the MiMI plug-in.
2) Pathway Studio v9 (Ariadne, Rockville, MD)
The second set of biological networks in this study was
created using Pathway Studio 9.0 software (http://www.
elsevier.com/online-tools/pathway-studio). The molecular
interaction data were extracted by Elsevier's MedScan
text-mining software, which contains almost 30 million
biological articles and abstracts.Additional files
Additional file 1: Table S1. Primer sequences for variants validation.
Additional file 2: Table S2. Biological information of the 19 proteins
harbouring the 19 validated sites. Known biological functions of the proteins
were obtained from Kyoto Encyclopedia of Genes and Genomes (KEGG) and
The Gene Ontology (GO) project (http://www.geneontology.org/).
Additional file 3: Table S3. The information of 19 validated sites. Five
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